SCHEMBL1534095

SCHEMBL1534095

COc1ccc(C(F)(F)F)c(C)c1C(=O)Oc1ccccc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 2/20 0.41
MAPT P10636 4/20 0.40
NPSR1 Q6W5P4 3/20 0.40
RAB9A P51151 2/20 0.39
TAS2R14 Q9NYV8 1/20 0.39
SCN10A Q9Y5Y9 1/20 0.39
NPC1 O15118 1/20 0.39
LMNA P02545 1/20 0.39
GAA P10253 1/20 0.39
ATM Q13315 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.38
CA12 O43570 1/20 0.38
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
CA7 P43166 1/20 0.38
CA9 Q16790 1/20 0.38
CA14 Q9ULX7 1/20 0.38
MRGPRX4 Q96LA9 1/20 0.38
ALPL P05186 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19634982 0.85 MAOB (0.43) MAOBMAPTNPSR1RAB9ATAS2R14
SCHEMBL11908685 0.84 POLB (0.47) MAPTNPSR1RAB9ANPC1GAA
SCHEMBL1534112 0.84 ALPL (0.47) MAPTNPSR1RAB9ANPC1GAA
SCHEMBL1534042 0.84 RXRA (0.46) MAPTSMN1; SMN2L3MBTL1CA9MRGPRX4
SCHEMBL1534069 0.84 ELANE (0.39) MAOBMAPTNPSR1RAB9ATAS2R14
SCHEMBL1534079 0.83 HSD17B10 (0.44) MAOBMAPTNPSR1RAB9ATAS2R14
SCHEMBL175435 0.82 MAPT (0.42) MAPTNPSR1RAB9ANPC1LMNA
SCHEMBL1534127 0.81 CA12 (0.50) MAOBMAPTRAB9ATAS2R14SCN10A
SCHEMBL1457189 0.77 MAPT (0.47) MAPTNPSR1RAB9AL3MBTL1CA12
SCHEMBL13520112 0.77 MAPT (0.40) MAPTNPSR1RAB9ANPC1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3275861-A1 TETRACYCLINE COMPOUNDS Tetraphase Pharmaceuticals, Inc. (US) 2018-01-31 EP disclosed
EP-3275861-A1 TETRACYCLINE COMPOUNDS Tetraphase Pharmaceuticals, Inc. (US) 2018-01-31 EP disclosed
US-20170334841-A1 TETRACYCLINE COMPOUNDS TETRAPHASE PHARMACEUTICALS, INC. 2017-11-23 US disclosed
US-20170334841-A1 TETRACYCLINE COMPOUNDS TETRAPHASE PHARMACEUTICALS, INC. 2017-11-23 US disclosed
US-20170334841-A1 TETRACYCLINE COMPOUNDS TETRAPHASE PHARMACEUTICALS, INC. 2017-11-23 US disclosed
EP-2470500-B1 TETRACYCLINE COMPOUNDS TETRAPHASE PHARMACEUTICALS INC (US) 2017-10-04 EP disclosed
US-9624166-B2 Tetracycline compounds TETRAPHASE PHARMACEUTICALS, INC. (US) 2017-04-18 US disclosed
US-20120208788-A1 Tetracycline Compounds TETRAPHASE PHARMACEUTICALS, INC. 2012-08-16 US disclosed
EP-2470500-A2 TETRACYCLINE COMPOUNDS Tetraphase Pharmaceuticals, Inc. (US) 2012-07-04 EP disclosed
WO-2011025982-A2 TETRACYCLINE COMPOUNDS TETRAPHASE PHARMACEUTICALS, INC. (US) 2011-03-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170334841-A1 TETRACYCLINE COMPOUNDS TUBB, TUBA1A, TUBA1C MAOB 1699/4885MAPT 93/4885NPSR1 4160/4885
US-20120208788-A1 Tetracycline Compounds TUBA1A, TUBA1C, TUBB1 MAOB 2000/4885MAPT 116/4885NPSR1 4147/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.